- Osteogenesis imperfecta treatments, encompassing pharmacologic agents such as bisphosphonates and denosumab, are increasingly vital components of rare disease management strategies in both pediatric and adult populations due to their ability to strengthen bone mass, reduce fracture frequency, and improve mobility outcomes
- The escalating demand for osteogenesis imperfecta treatments is primarily fueled by improved diagnostic capabilities, increasing global awareness of rare genetic disorders, supportive regulatory frameworks for orphan drugs, and rising investments in novel therapies such as gene-based interventions and monoclonal antibodies
- North America dominates the osteogenesis imperfecta treatment market with the largest revenue share of 52.5% in 2024, characterized by well-established healthcare infrastructure, high per capita health expenditure, and strong presence of research-focused pharmaceutical companies
- Asia-Pacific is expected to be the fastest growing region in the osteogenesis imperfecta treatment market during the forecast period due to increasing healthcare access, rising public and private investments in rare disease treatment, and growing awareness and diagnosis rates across developing nations
- Intravenous segment dominates the osteogenesis imperfecta treatment market with a market share of 51.5% in 2024, driven by its rapid therapeutic action, higher bioavailability, and frequent use in administering bisphosphonates in clinical settings
